Also known as Tygacil
Tigecycline (INN) is a glycylcycline antibiotic developed by Francis Tally and marketed by Wyeth under the brand name Tygacil. It was given a U.S. Food and Drug Administration (FDA) fast-track approval and was approved on June 17, 2005. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus and Acinetobacter baumannii. The New Delhi metallo-β-Lactamase multidrug-resistant Enterobacteriaceae has also shown susceptibility to tigecycline.Source: Wikipedia
Estimated Total Cost: $931.05 for an average of 7 days supply
Patients are most commonly prescribed tigecycline to treat pyogenic skin infection, chronic ulcer, rabies, and blastomycosis.